Effect of Carvedilol and Nebivolol on Oxidative Stress-related Parameters and Endothelial Function in Patients with Essential Hypertension

Basic and Clinical Pharmacology and Toxicology

Volumn 111, Issue 5, 2012, Pages 309-316

  Zepeda, Ramiro J ^a   Castillo, Rodrigo ^a   Rodrigo, Ramón ^a   Prieto, Juan C ^a,b   Aramburu, Ivonne ^b   Brugere, Solange ^b   Galdames, Katia ^b   Noriega, Viviana ^b,c   Miranda, Hugo F ^a,c  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^c UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; GLUTATHIONE; GLUTATHIONE DISULFIDE; NEBIVOLOL; NITRIC OXIDE; NITRITE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BENZOPYRANS; CARBAZOLES; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; FEMALE; GLUTATHIONE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROPANOLAMINES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; VASODILATOR AGENTS;

EID: 84867656413     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2012.00911.x     Document Type: Article

References (50)

1. Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M et al. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension. Hypertens Res 2007;30:307-13.
2. Waeber B, Brunner HR ; Joint National Committee in the US (JNC-VI); World Health Organization - International Society of Hypertension (WHO-ISH). The multi-factorial nature of hypertension: the greatest challenge for its treatment? J Hypertens Suppl 2001;19:S9-16.
3. Ferroni P, Basili S, Paoletti V, Davì G Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr Metab Cardiovasc Dis 2006;16:222-33.
4. Plante GE Vascular response to stress in health and disease. Metabolism 2002;51:25-30.
5. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J Cardiovasc Pharmacol 2003;42:453-61.
6. Yarlioglues M, Kaya MG, Ardic I, Dogdu O, Kasapkara HA, Gunturk E et al. Relationship between mean platelet volume levels and subclinical target organ damage in newly diagnosed hypertensive patients. Blood Press 2011;20:92-7.
7. Tomiyama H, Higashi Y, Takase B, Node K, Sata M, Inoue T et al. Relationships among hyperuricemia, metabolic syndrome, and endothelial function. Am J Hypertens 2011;24:770-4.
8. Syvänen K, Korhonen P, Partanen A, Aarnio P Endothelial function in a cardiovascular risk population with borderline ankle-brachial index. Vasc Health Risk Manag 2011;7:97-101.
9. Tycinska AM, Mroczko B, Musial WJ, Sawicki R, Kaminski K, Borowska H et al. Blood pressure in relation to neurogenic, inflammatory and endothelial dysfunction biomarkers in patients with treated essential arterial hypertension. Adv Med Sci 2011;56:80-7.
10. Ignarro LJ, Napoli C Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Diab Rep 2005;5:17-23.
11. Hermann M, Flammer A, Lüscher TF Nitric oxide in hypertension. J Clin Hypertens (Greenwich) 2006;8:17-29.
12. Spieker LE, Flammer AJ, Lüscher TF The vascular endothelium in hypertension. Handb Exp Pharmacol 2006;176:249-83.
13. Zeng C, Villar VA, Yu P, Zhou L, Jose PA Reactive oxygen species and dopamine receptor function in essential hypertension. Clin Exp Hypertens 2009;31:156-78.
14. Cockcroft J Nebivolol: a review. Expert Opin Pharmacother 2004;5:893-9.
15. Papademetriou V Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. Am J Cardiol 2009;103:273-8.
16. Baldwin CM, Keam SJ Nebivolol: in the treatment of hypertension in the US. Am J Cardiovasc Drugs 2009;9:253-60.
17. Greathouse M Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol 2010;33:20-7.
18. Virdis A, Ghiadoni L, Taddei S Effects of antihypertensive treatment on endothelial function. Curr Hypertens Rep 2011;13:276-81.
19. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010;182:652-60.
20. Kametani R, Miura T, Harada N, Shibuya M, Wang R, Tan H et al. Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria. Circ J 2006;70:321-6.
21. Mason RP, Giles TD, Sowers JR Evolving mechanisms of action of beta blockers: focus on nebivolol. J Cardiovasc Pharmacol 2009;54:123-8.
22. Ram CV Beta-blockers in hypertension. Am J Cardiol 2010;106:1819-25.
23. O'Brien E, Mee F, Atkins N, O'Malley K Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society protocol. J Hypertens 1991;9:573-4.
24. Groppelli A, Omboni S, Parati G, Mancia G Evaluation of noninvasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24-hour intra-arterial blood pressure. Hypertension 1992;20:227-32.
25. Moriguchi J, Itoh H, Harada S, Takeda K, Hatta T, Nakata T et al. Low frequency regular exercise improves flow-mediated dilatation of subjects with mild hypertension. Hypertens Res 2005;28:315-21.
26. Ito H, Nagatomo Y, Kohno T, Anzai T, Meguro T, Ogawa S et al. Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. Circ J 2010;74:1578-83.
27. Bennett BM, Kobus SM, Brien JF, Nakatsu K, Marks GS Requirement for reduced, unliganded hemoprotein for the hemoglobin- and myoglobin-mediated biotransformation of glyceryl trinitrate. J Pharmacol Exp Ther 1986;237:629-35.
28. Benzie IF, Strain JJ The ferric reducing ability of plasma (FRAP) as a measure of 'antioxidant power': the FRAP assay. Anal Biochem 1996;239:70-6.
29. Hissin PJ, Hilf R A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976;74:214-26.
30. Ohkawa H, Ohishi N, Yagi K Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
31. Milne GL, Musiek ES, Morrow JD F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005;10:10-23.
32. Dawes M, Brett SE, Chowienczyk PJ, Mant TG, Ritter JM The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999;48:460-3.
33. Parenti A, Filippi S, Amerini S, Granger HJ, Fazzini A, Ledda F Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000;292:698-703.
34. Dandona P, Ghanim H, Brooks DP Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007;25:731-41.
35. Aronow WS Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010;11:2599-607.
36. Weber MA, Sica DA, Tarka EA, Iyengar M, Fleck R, Bakris GL Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol 2006;98:32L-8L.
37. Landmesser U, Drexler H The clinical significance of endothelial dysfunction. Curr Opin Cardiol 2005;20:547-51.
38. Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 2000;140:753-9.
39. Tzemos N, Lim PO, MacDonald TM Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001;104:511-4.
40. Pasini AF, Garbin U, Stranieri C, Boccioletti V, Mozzini C, Manfro S et al.Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008;21:1251-7.
41. Schmidt AC, Graf C, Brixius K, Scholze J Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig 2007;27:841-9.
42. Wehland M, Grosse J, Simonsen U, Infanger M, Bauer J, Grimm D The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease. Curr Vasc Pharmacol 2012;10:378-90.
43. Fahlbusch SA, Tsikas D, Mehls C, Gutzki FM, Boger RH, Frolich JC et al.Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers. Eur J Clin Pharmacol 2004;60:83-8.
44. Xiaozhen H, Yun Z, Mei Z, Yu S Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Press 2010;19:40-7.
45. Manrique C, Giles TD, Ferdinand KC, Sowers JR Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens (Greenwich) 2009;11:369-75.
46. Afonso RA, Patarrao RS, Macedo MP, Carmo MM Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens 2006;19:419-25.
47. Ignarro LJ Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol. Cardiovasc Ther 2008;26:115-34.
48. Russo C, Olivieri O, Girelli D, Faccini G, Zenari ML, Lombardi S Anti-oxidant status and lipiperoxidation in patients with essential hypertension. J Hypertens 1998;16:1267-71.
49. Rodrigo R, Bachler JP, Araya J, Prat H, Passalacqua W Relationship between (Na+K)-ATPase activity, lipid peroxidation and fatty acid profile in erythrocytes of hypertensive and normotensive subjects. Mol Cell Biochem 2007;303:73-81.
50. Cracowski JL, Durand T Cardiovascular pharmacology and physiology of the isoprostanes. Fundam Clin Pharmacol 2006;20:417-27.